Jindong Sheng

521 total citations
17 papers, 400 citations indexed

About

Jindong Sheng is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Jindong Sheng has authored 17 papers receiving a total of 400 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 6 papers in Pulmonary and Respiratory Medicine and 6 papers in Oncology. Recurrent topics in Jindong Sheng's work include Cancer Immunotherapy and Biomarkers (4 papers), Epigenetics and DNA Methylation (3 papers) and Hormonal and reproductive studies (3 papers). Jindong Sheng is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), Epigenetics and DNA Methylation (3 papers) and Hormonal and reproductive studies (3 papers). Jindong Sheng collaborates with scholars based in China, United States and Hong Kong. Jindong Sheng's co-authors include Baoguo Liu, Jie Jin, Zheming Lu, Wei Yu, Qun He, Yun Cui, Yu Fan, Fangxuan Li, Wenjun Yang and Wenke Han and has published in prestigious journals such as PLoS ONE, International Journal of Cancer and Frontiers in Immunology.

In The Last Decade

Jindong Sheng

17 papers receiving 396 citations

Peers

Jindong Sheng

PRM

EDM

ONCOL

Minghua Ge China

Feng Cai China

Hsi Chin Wu Taiwan

Yuki Katsuya Japan

Lingmi Hou China

Emily Siegel United States

Yuansheng Duan China

Jasmin Meier Germany

Grażyna Drabik Poland

María San Román Spain

Minghua Ge China

Jindong Sheng

148 ×1.0

50 ×0.5

PRM

135 ×1.4

EDM

62 ×0.8

ONCOL

56 ×0.7

Citations per year, relative to Jindong Sheng Jindong Sheng (= 1×) peers Minghua Ge

Countries citing papers authored by Jindong Sheng

Since Specialization

Citations

This map shows the geographic impact of Jindong Sheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jindong Sheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jindong Sheng more than expected).

Fields of papers citing papers by Jindong Sheng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jindong Sheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jindong Sheng. The network helps show where Jindong Sheng may publish in the future.

Co-authorship network of co-authors of Jindong Sheng

This figure shows the co-authorship network connecting the top 25 collaborators of Jindong Sheng. A scholar is included among the top collaborators of Jindong Sheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jindong Sheng. Jindong Sheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Sheng, Jindong, Haitao Luo, Xiangyu Liu, et al.. (2025). Tislelizumab (anti-PD-1) plus chemotherapy as neoadjuvant therapy for patients with stage IB3/IIA2 cervical cancer (NATIC): a prospective, single-arm, phase II study. Signal Transduction and Targeted Therapy. 10(1). 215–215. 2 indexed citations

Wu, Huijuan, Lu Sun, Dan Li, et al.. (2024). RPL35A drives ovarian cancer progression by promoting the binding of YY1 to CTCF promoter. Journal of Cellular and Molecular Medicine. 28(6). e18115–e18115. 4 indexed citations

Chen, Shengbin, Jindong Sheng, Wei Yu, et al.. (2024). YAP-mediated GPER signaling impedes proliferation and survival of prostate epithelium in benign prostatic hyperplasia. iScience. 27(3). 109125–109125. 7 indexed citations

Zhang, Lei, Wei Zhao, Jinke Huang, et al.. (2022). Development of a Dendritic Cell/Tumor Cell Fusion Cell Membrane Nano-Vaccine for the Treatment of Ovarian Cancer. Frontiers in Immunology. 13. 828263–828263. 33 indexed citations

Song, Hualin, Tianjie Li, Jindong Sheng, et al.. (2022). Necroptosis-Related miRNA Biomarkers for Predicting Overall Survival Outcomes for Endometrial Cancer. Frontiers in Genetics. 13. 828456–828456. 3 indexed citations

Sheng, Jindong, Shuai Hu, Yun Cui, et al.. (2022). Estrogen and G protein-coupled estrogen receptor accelerate the progression of benign prostatic hyperplasia by inducing prostatic fibrosis. Cell Death and Disease. 13(6). 533–533. 33 indexed citations

Chen, Ying, Lei Zhang, Fangxuan Li, et al.. (2021). Combination of Chemotherapy and Photodynamic Therapy with Oxygen Self-Supply in the Form of Mutual Assistance for Cancer Therapy. International Journal of Nanomedicine. Volume 16. 3679–3694. 27 indexed citations

Sheng, Jindong, Zhenhua Liu, Yu Fan, et al.. (2021). Potent antitumour of the mTORC1/2 dual inhibitor AZD2014 in docetaxel‐sensitive and docetaxel‐resistant castration‐resistant prostate cancer cells. Journal of Cellular and Molecular Medicine. 25(5). 2436–2449. 23 indexed citations

Yang, Yang, Jindong Sheng, Qun He, et al.. (2019). Infiltrating CD4+ T cells attenuate chemotherapy sensitivity in prostate cancer via CCL5 signaling. The Prostate. 79(9). 1018–1031. 39 indexed citations

10.

Liu, Jie, Yang Yang, Jindong Sheng, et al.. (2019). Activation of cGMP/PKG/p65 signaling associated with PDE5‐Is downregulates CCL5 secretion by CD8⁺ T cells in benign prostatic hyperplasia. The Prostate. 79(8). 909–919. 13 indexed citations

11.

Sheng, Jindong, Yun Cui, Shiming He, et al.. (2018). M2 macrophage-mediated interleukin-4 signalling induces myofibroblast phenotype during the progression of benign prostatic hyperplasia. Cell Death and Disease. 9(7). 755–755. 38 indexed citations

12.

Lu, Zheming, Chaoting Zhang, Jindong Sheng, Jing Shen, & Baoguo Liu. (2017). T cell receptor β‐chain repertoire analysis reveals the association between neoantigens and tumour‐infiltrating lymphocytes in multifocal papillary thyroid carcinoma. International Journal of Cancer. 141(2). 377–382. 15 indexed citations

13.

Wang, Lu, Yun Cui, Jindong Sheng, et al.. (2017). Epigenetic inactivation ofHOXA11, a novel functional tumor suppressor for renal cell carcinoma, is associated with RCC TNM classification. Oncotarget. 8(13). 21861–21870. 20 indexed citations

14.

Lu, Zheming, Yujie Zhang, Dongdong Feng, et al.. (2017). Targeted next generation sequencing identifies somatic mutations and gene fusions in papillary thyroid carcinoma. Oncotarget. 8(28). 45784–45792. 36 indexed citations

15.

Wang, Lu, Yun Cui, Lian Zhang, et al.. (2016). The Silencing of CCND2 by Promoter Aberrant Methylation in Renal Cell Cancer and Analysis of the Correlation between CCND2 Methylation Status and Clinical Features. PLoS ONE. 11(9). e0161859–e0161859. 18 indexed citations

16.

Lu, Zheming, Jindong Sheng, Yujie Zhang, et al.. (2016). Clonality analysis of multifocal papillary thyroid carcinoma by using genetic profiles. The Journal of Pathology. 239(1). 72–83. 56 indexed citations

17.

Herman, James G., Malcolm V. Brock, Jindong Sheng, et al.. (2014). Methylation of DACT2 Promotes Papillary Thyroid Cancer Metastasis by Activating Wnt Signaling. PLoS ONE. 9(11). e112336–e112336. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact